文献速递心力衰竭与心肌病

2022年ACC/AHA/HFSA心衰分期标准对社区队列心衰分期的影响

Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该研究基于MESA、CHS和FHS三个纵向队列共11618名参与者,比较2013年与2022年ACC/AHA/HFSA心衰分期标准的分布与预后。2022标准使B期(前心衰)比例从15.9%升至43.2%,且女性及西班牙裔、黑人个体比例更高;B期患者进展为症状性心衰的相对风险仍相似(HR 10.61,95%CI 9.00-12.51,P<0.001)。

要点

  • 2022标准使社区人群中B期心衰比例大幅增加(15.9%→43.2%)。
  • B期比例上升在女性及西班牙裔、黑人个体中更为明显。
  • 新标准下B期患者进展为症状性心衰的风险仍高(HR 10.61)。

核心结论

  • 新分期标准导致大量社区个体从A期转移至B期,且新标准下B期患者进展为症状性心衰风险高。

研究设计与样本

  • 研究纳入MESA、CHS和FHS三个纵向队列共11618名参与者,按2013和2022年ACC/AHA/HFSA标准进行心衰分期。
  • 采用Cox比例风险回归评估进展至症状性心衰的预测因素及各分期相关不良临床结局。

主要发现

  • 按2022标准,11618名参与者中健康者1943人(16.7%),A期4348人(37.4%),B期5019人(43.2%),C/D期308人(2.7%)。
  • 与2013年标准相比,2022标准使B期比例从15.9%升至43.2%,且该变化在女性及西班牙裔、黑人个体中比例更高。
  • 尽管2022标准下B期人群比例更大,但进展为症状性心衰的相对风险仍相似(HR 10.61;95%CI 9.00-12.51;P<0.001)。

临床怎么用

  • 临床中采用2022标准可将更多社区个体识别为B期(前心衰),尤其女性和西班牙裔、黑人个体。
  • 对新标准下B期患者应重视其高进展风险,加强监测与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) clinical practice guideline proposed an updated definition for heart failure (HF) stages. OBJECTIVES: This study aimed to compare prevalence and prognosis of HF stages according to classification/definition originally described in 2013 and 2022 ACC/AHA/HFSA definitions. METHODS: Study participants from 3 longitudinal cohorts (the MESA [Multi-Ethnic Study of Atherosclerosis], CHS [Cardiovascular Health Study], and the FHS [Framingham Heart Study]), were categorized into 4 HF stages according to the 2013 and 2022 criteria. Cox proportional hazards regression was used to assess predictors of progression to symptomatic HF and adverse clinical outcomes associated with each HF stage. RESULTS: Among 11,618 study participants, according to the 2022 staging, 1,943 (16.7%) were healthy, 4,348 (37.4%) were in stage A (at risk), 5,019 (43.2%) were in stage B (pre-HF), and 308 (2.7%) were in stage C/D (symptomatic HF). Compared to the classification/definition originally described in 2013, the 2022 ACC/AHA/HFSA approach resulted in a higher proportion of individuals with stage B HF (increase from 15.9% to 43.2%); this shift disproportionately involved women as well as Hispanic and Black individuals. Despite the 2022 criteria designating a greater proportion of individuals as stage B, the relative risk of progression to symptomatic HF remained similar (HR: 10.61; 95% CI: 9.00-12.51; P < 0.001). CONCLUSIONS: New standards for HF staging resulted in a substantial shift of community-based individuals from stage A to stage B. Those with stage B HF in the new system were at high risk for progression to symptomatic HF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mohebi, Wang, Lau, et al. Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort. J Am Coll Cardiol. 2023. PMID: 37286252. doi:10.1016/j.jacc.2023.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。